Bovine Colostrum in Prevention of Sepsis and Retinopathy of Prematurity
Primary Purpose
Preterm
Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
The bovine colostrum ( trade name : baby steps sachets, 300mg )
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Preterm focused on measuring Premature infants, colostrum, ROP
Eligibility Criteria
Inclusion Criteria:
- Preterm infants ≤ 32 weeks gestational age, weight ≤ 1500 gm. Start feeding in the first 72 hours of life
Exclusion Criteria:
- Exclusion criteria
Patients with any of the following will be excluded:
- Obvious major congenital abnormalities.
- Infants expected to be >72 hours of age at the time of randomization.
- Parental consent lacking/refusal
Sites / Locations
- Alexandria university, Elshattbi hospital
- Marwa Mohamed Farag
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Group I: bovine colostrum group
group II : control group
Arm Description
Outcomes
Primary Outcome Measures
Fundus examination to detect retinopathy of prematurity
ROP screen will be performed by ophthalmologist to detect zone stage extension and severity of the disease
Secondary Outcome Measures
prematurity related complications
late onset sepsis
IVH
Necrotizing enterocolitis
bronchopulmonary dysplasia
Assessment of weight
-Assessment of weight every other day.
-Assessment of Head circumference
measurement of Head circumference weekly.
-Assessment of length
-Assessment of length on admission and on discharge.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05438680
Brief Title
Bovine Colostrum in Prevention of Sepsis and Retinopathy of Prematurity
Official Title
Evaluation of the Effect of Bovine Colostrum in Prevention of Late Onset Sepsis and Retinopathy of Prematurity
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
June 20, 2022 (Actual)
Primary Completion Date
September 20, 2023 (Actual)
Study Completion Date
October 1, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Alexandria University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to evaluate efficacy of bovine colostrum administration as a prophylaxis to decrease the incidence and the occurrence of retinopathy of prematurity in preterm neonates of gestational age less than 32 weeks during their hospital stay.
Detailed Description
This study will include a randomized controlled trial carried out on preterm neonates who will fulfill the eligibility criteria delivered at Alexandria University Children's Hospital. Evaluation of the outcome will be done only for those who admitted to the neonatal intensive care unit (NICU) at Alexandria University Children's Hospital.
The study will be carried out in 4 phases:
First phase: Enrollment and selection phase.
Second phase: Intervention phase ( enteral bovine colostrum administration) .
Third phase: Evaluation phase.
Fourth phase: collected data analysis and results.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm
Keywords
Premature infants, colostrum, ROP
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Masking controlled clinical trial will be used to assess the effect of prophylactic bovine colostrum in preventing retinopathy of prematurity.
Masking
Participant
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group I: bovine colostrum group
Arm Type
Active Comparator
Arm Title
group II : control group
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
The bovine colostrum ( trade name : baby steps sachets, 300mg )
Intervention Description
The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.
Enteral route, either through nasogastric tube or orally.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
distilled water with no bovine colostrum
Primary Outcome Measure Information:
Title
Fundus examination to detect retinopathy of prematurity
Description
ROP screen will be performed by ophthalmologist to detect zone stage extension and severity of the disease
Time Frame
28 days
Secondary Outcome Measure Information:
Title
prematurity related complications
Description
late onset sepsis
IVH
Necrotizing enterocolitis
bronchopulmonary dysplasia
Time Frame
28 days
Title
Assessment of weight
Description
-Assessment of weight every other day.
Time Frame
28 days
Title
-Assessment of Head circumference
Description
measurement of Head circumference weekly.
Time Frame
28 days
Title
-Assessment of length
Description
-Assessment of length on admission and on discharge.
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Hour
Maximum Age & Unit of Time
3 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Preterm infants ≤ 32 weeks gestational age, weight ≤ 1500 gm. Start feeding in the first 72 hours of life
Exclusion Criteria:
Exclusion criteria
Patients with any of the following will be excluded:
Obvious major congenital abnormalities.
Infants expected to be >72 hours of age at the time of randomization.
Parental consent lacking/refusal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamed Alaaaldin Thabet, PhD
Organizational Affiliation
Faculty of medicine, Alexandria University, Egypt
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Islam Shereen Hamdy, PhD
Organizational Affiliation
Faculty of medicine, Alexandria University, Egypt
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eman Shabban Mohamed, MBBCh
Organizational Affiliation
Faculty of medicine, Alexandria University, Egypt
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marwa Mohamed Farag, PhD
Organizational Affiliation
Faculty of medicine, Alexandria University, Egypt
Official's Role
Study Chair
Facility Information:
Facility Name
Alexandria university, Elshattbi hospital
City
Alexandria
ZIP/Postal Code
0354
Country
Egypt
Facility Name
Marwa Mohamed Farag
City
Alexandria
ZIP/Postal Code
0356
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Bovine Colostrum in Prevention of Sepsis and Retinopathy of Prematurity
We'll reach out to this number within 24 hrs